Piero Pollesello

Piero Pollesello

UNVERIFIED PROFILE

Are you Piero Pollesello?   Register this Author

Register author
Piero Pollesello

Piero Pollesello

Publications by authors named "Piero Pollesello"

Are you Piero Pollesello?   Register this Author

60Publications

1034Reads

-Profile Views

Use of levosimendan in acute heart failure.

Eur Heart J Suppl 2018 Dec 11;20(Suppl I):I2-I10. Epub 2018 Dec 11.

Second Cardiology Department and Heart Failure Unit, Attikon Teaching Hospital, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/suy039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288642PMC
December 2018

Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations.

Expert Rev Cardiovasc Ther 2016 Dec 25;14(12):1335-1347. Epub 2016 Oct 25.

c Department of Internal Medicine, Division of Cardiology , Medical University of Graz , Graz , Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14779072.2016.1247694DOI Listing
December 2016

Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay.

PLoS One 2015 16;10(4):e0124742. Epub 2015 Apr 16.

Laboratory of Physiology and Experimental Surgery, Department of Translational Medicine, University Eastern Piedmont "Amedeo Avogadro", Via Solaroli 17, Azienda Ospedaliera Universitaria Maggiore della Carità, corso Mazzini 36, Novara, Italy.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0124742PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400069PMC
April 2016

Efficacy of selective NCX inhibition by ORM-10103 during simulated ischemia/reperfusion.

Eur J Pharmacol 2014 Oct 27;740:539-51. Epub 2014 Jun 27.

Department of Pharmacology & Pharmacotherapy, University of Szeged, Dóm tér 12., 6722 Szeged, Hungary; MTA-SZTE Research Group of Cardiovascular Pharmacology, Hungarian Academy of Sciences, Szeged, Hungary. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2014.06.033DOI Listing
October 2014

Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus.

J Cardiovasc Pharmacol 2014 Sep;64(3):199-208

*Division of Clinical Physiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; and †Critical Care, Proprietary Products Division, Orion Pharma, Orion Corporation, Espoo, Finland.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232335PMC
September 2014

Levosimendan and its metabolite OR-1896 elicit KATP channel-dependent dilation in resistance arteries in vivo.

Pharmacol Rep 2013 ;65(5):1304-10

Division of Clinical Physiology, Institute of Cardiology, Medical and Health Science Center, University of Debrecen, Móricz Zs. krt. 22, H-4032 Debrecen, Hungary.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016981PMC
August 2014

Protective effects elicited by levosimendan against liver ischemia/reperfusion injury in anesthetized rats.

Liver Transpl 2014 Mar 27;20(3):361-75. Epub 2014 Jan 27.

Physiology Laboratory, Department of Translational Medicine, A. Avogadro University of East Piedmont, Novara, Italy; Experimental Surgery, Azienda Ospedaliera Universitaria Maggiore della Carità, Novara, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/lt.23799DOI Listing
March 2014

Drug discovery and development for acute heart failure drugs: are expectations too high?

Authors:
Piero Pollesello

Int J Cardiol 2014 Mar 4;172(1):11-3. Epub 2014 Jan 4.

Orion Pharma, Critical Care, P.O. Box 65, Espoo, Finland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2013.12.136DOI Listing
March 2014

Lessons from Lisbon on AHF drug treatment: is it really true that all-old-failed-all-new-will-succeed?

Int J Cardiol 2013 Oct 23;168(5):4798-9. Epub 2013 Jul 23.

Critical Care Proprietary Products Division, Orion Pharma, PO Box 65, FIN-02101 Espoo, Finland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2013.07.042DOI Listing
October 2013

The clinical effects of levosimendan are not attenuated by sulfonylureas.

Scand Cardiovasc J 2012 Dec 25;46(6):330-8. Epub 2012 Sep 25.

Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/14017431.2012.725206DOI Listing
December 2012

Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy.

Adv Ther 2012 Dec 6;29(12):1037-50. Epub 2012 Dec 6.

Springer Healthcare, via Lanino 5, 20144, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-012-0070-4DOI Listing
December 2012

Prolonged antispasmodic effect in isolated radial artery graft and pronounced platelet inhibition induced by the inodilator drug, levosimendan.

Basic Clin Pharmacol Toxicol 2012 Mar 21;110(3):269-74. Epub 2011 Oct 21.

Department of Pharmacology and Pharmacotherapy, University of Szeged, Dóm tér 12, Szeged, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1742-7843.2011.00801.xDOI Listing
March 2012

Absence of mitochondrial activation during levosimendan inotropic action in perfused paced guinea pig hearts as demonstrated by modular control analysis.

Am J Physiol Regul Integr Comp Physiol 2010 Sep 30;299(3):R786-92. Epub 2010 Jun 30.

Résonance Magnétique des Systèmes Biologiques, UMR5536 CNRS, Université Victor Segalen Bordeaux 2, 146 rue Léo-Saignat, 33076 Bordeaux cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpregu.00184.2010DOI Listing
September 2010

Effects of levosimendan on the energy balance: preclinical and clinical evidence.

J Cardiovasc Pharmacol 2009 Apr;53(4):302-10

Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0b013e31819c9a17DOI Listing
April 2009

The cardioprotective effects of levosimendan: preclinical and clinical evidence.

J Cardiovasc Pharmacol 2007 Sep;50(3):257-63

Orion Pharma, Cardiology and Critical Care, Espoo, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0b013e3180986230DOI Listing
September 2007

Preconditioning effects of levosimendan in a rabbit cardiac ischemia-reperfusion model.

J Cardiovasc Pharmacol 2006 Oct;48(4):148-52

Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical Center, University of Szeged, Szeged, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.fjc.0000246151.39758.2aDOI Listing
October 2006

The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles.

Br J Pharmacol 2006 Jul 22;148(5):696-702. Epub 2006 May 22.

Division of Clinical Physiology, Institute of Cardiology, University of Debrecen, Debrecen H-4004, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.bjp.0706781DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1751872PMC
July 2006

The effect of levosimendan during long-term amiodarone treatment in dogs.

Basic Clin Pharmacol Toxicol 2006 Jul;99(1):27-32

Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical Center, University of Szeged, H-6701 Szeged, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1742-7843.2006.pto_394.xDOI Listing
July 2006

Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs.

J Cardiovasc Pharmacol Ther 2006 Jun;11(2):129-35

Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical Center, University of Szeged, Szeged, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248406289286DOI Listing
June 2006

Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure.

Am J Physiol Heart Circ Physiol 2006 May 16;290(5):H2007-14. Epub 2005 Dec 16.

Department of Physiology and Biophysics, Faculty of Medicine, Technion, Isreal Institute of Technology, Haifa, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpheart.00600.2005DOI Listing
May 2006

Pharmacological mechanisms contributing to the clinical efficacy of levosimendan.

Cardiovasc Drug Rev 2005 ;23(1):71-98

Division of Clinical Physiology, Institute of Cardiology, University of Debrecen, Medical and Health Science Center, Medical School, P.O. BOX 1, H-4004 Debrecen, Hungary.

View Article

Download full-text PDF

Source
October 2005

Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone.

J Cardiovasc Pharmacol 2005 Sep;46(3):369-76

Division of Clinical Physiology, Institute of Cardiology, University of Debrecen, Medical and Health Science Center, Faculty of Medicine, Debrecen, Hungary.

View Article

Download full-text PDF

Source
September 2005

Structure of the exopolysaccharide produced by Enterobacter amnigenus.

Carbohydr Res 2005 Feb;340(3):439-47

Department of Biochemistry, Biophysics and Macromolecular Chemistry, University of Trieste, via L. Giorgieri 1, I-34127 Trieste, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.carres.2004.12.008DOI Listing
February 2005

ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction.

Curr Opin Crit Care 2004 Dec;10(6):436-41

Orion-Pharma, Cardiovascular and Critical Care, Espoo, Finland.

View Article

Download full-text PDF

Source
December 2004

The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c.

Mol Cell Biochem 2004 Nov;266(1-2):87-107

Orion Pharma, Cardiovascular Research, Espoo, Finland.

View Article

Download full-text PDF

Source
November 2004

Potassium-specific effects of levosimendan on heart mitochondria.

Biochem Pharmacol 2004 Sep;68(5):807-12

Institute for Biomedical Research, Kaunas University of Medicine, Kaunas, Lithuania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2004.05.018DOI Listing
September 2004

Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion.

J Cardiovasc Pharmacol 2004 Sep;44(3):316-21

Institute of Biomedicine/Biochemistry, Biomedicum, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
September 2004

A cellular UDP-glucose deficiency causes overexpression of glucose/oxygen-regulated proteins independent of the endoplasmic reticulum stress elements.

J Biol Chem 2004 May 12;279(21):21724-31. Epub 2004 Mar 12.

Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M312791200DOI Listing
May 2004

Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart.

J Cardiovasc Pharmacol 2004 Apr;43(4):555-61

Orion Pharma, Espoo, Finland.

View Article

Download full-text PDF

Source
April 2004

Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization.

Eur J Pharmacol 2004 Feb;486(1):1-8

Discovery Biology, Orion Pharma, P.O. Box 65, FIN-02101 Espoo, Finland.

View Article

Download full-text PDF

Source
February 2004

The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig.

Eur J Pharmacol 2004 Feb;486(1):67-74

Division of Clinical Physiology, Faculty of Medicine, Medical and Health Science Center, Institute of Cardiology, University of Debrecen, P.O. BOX 1, H-4004 Debrecen, Hungary.

View Article

Download full-text PDF

Source
February 2004

Complete structure analysis of OR-1746, a complex product of cyclocondensation of arylhydrazomalononitriles containing clusters of protonated and unprotonated nitrogens, by pulsed-field-gradient heteronuclear NMR.

J Pharm Biomed Anal 2003 Feb;31(1):125-31

Orion Pharma, Cardiovascular Research and Development, P.O. Box 65, FIN-02101 Espoo, Finland.

View Article

Download full-text PDF

Source
February 2003

Structural and functional implications of the phospholamban hinge domain: impaired SR Ca2+ uptake as a primary cause of heart failure.

Cardiovasc Res 2002 Nov;56(2):248-59

Department of Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0575, USA.

View Article

Download full-text PDF

Source
November 2002

Structure of the 1-36 N-terminal fragment of human phospholamban phosphorylated at Ser-16 and Thr-17.

Biophys J 2002 Jul;83(1):484-90

Orion Pharma, Cardiovascular Research, FIN-02101 Espoo, Finland.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1302162PMC
http://dx.doi.org/10.1016/S0006-3495(02)75184-9DOI Listing
July 2002